1. Home
  2. RAVE vs TCRX Comparison

RAVE vs TCRX Comparison

Compare RAVE & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rave Restaurant Group Inc.

RAVE

Rave Restaurant Group Inc.

N/A

Current Price

$2.80

Market Cap

41.4M

ML Signal

N/A

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$0.32

Market Cap

49.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAVE
TCRX
Founded
1958
2018
Country
United States
United States
Employees
24
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.4M
49.4M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
RAVE
TCRX
Price
$2.80
$0.32
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
25.6K
1.1M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
12.28
EPS
0.15
N/A
Revenue
$15,120,000.00
$10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$19.81
P/E Ratio
$19.40
N/A
Revenue Growth
N/A
266.65
52 Week Low
$2.25
$0.29
52 Week High
$3.75
$2.57

Technical Indicators

Market Signals
Indicator
RAVE
TCRX
Relative Strength Index (RSI) 36.74 21.50
Support Level $2.71 N/A
Resistance Level $3.43 $0.82
Average True Range (ATR) 0.09 0.05
MACD -0.01 -0.01
Stochastic Oscillator 11.43 5.46

Price Performance

Historical Comparison
RAVE
TCRX

About RAVE Rave Restaurant Group Inc.

Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: